Alloferon-1 and Indolicidin Peptide Composition for Genital Herpes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for herpes simplex virus type 2 (HPV-2) infections, such as genital herpes, are inadequate due to low efficacy during inactive stages and insufficient impact on concomitant bacterial infections, with existing drugs like Acyclovir and Alloferon having limitations in parenteral administration and systemic side effects.
Innovation Solution
A topical pharmaceutical composition combining Alloferon 1 and indolicidin peptides in a 1:2 to 2:1 mass ratio, with excipients like Carbopol and allantoin, is developed for local application, enhancing immunomodulatory effects and biocidal activity against HPV-2 and bacterial infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If synthetic acyclic nucleosides like Acyclovir are used to treat HPV-2 infections, then HPV virus replication is disrupted, but the treatment has low efficacy at the inactive stage of the disease
Solution Approach 1:
The patent combines two distinct peptides with different mechanisms of action: Alloferon-1 (immunomodulatory) and indolicidin (direct biocidal). This combination allows the treatment to address both active replication and inactive latent stages of HPV-2, overcoming the limitation of single-agent therapies that only work during specific disease stages.
Solution Approach 2:
The dual-peptide composition creates a multi-functional treatment that simultaneously provides immunomodulation and direct antiviral/bacterial activity. This universal approach makes the treatment effective across diverse disease manifestations and stages, including inactive carriers, rather than being stage-specific.
2Reliability
If Alloferon is used for treatment, then immunomodulatory effects are achieved, but the preparation requires parenteral administration and has insufficient efficacy against concomitant infections
Solution Approach 1:
The patent merges Alloferon-1 with indolicidin peptide in a single topical composition. This combination enables both immunomodulation and direct biocidal activity against concomitant bacterial infections, eliminating the need for separate treatments and allowing topical application rather than parenteral administration.
Solution Approach 2:
The invention creates a composite pharmaceutical preparation containing two distinct peptides with complementary functions. This composite structure integrates the immunomodulatory properties of Alloferon-1 with the broad-spectrum biocidal activity of indolicidin, achieving multi-functionality in a single topical agent.
3Reliability
If existing antiviral drugs are used, then HPV virus replication is inhibited, but the virus survives in regional nerve ganglion and causes frequent relapses
Solution Approach 1:
The patent employs Alloferon-1 to stimulate the immune system in advance, enhancing NK cell and T-lymphocyte activity before viral relapses occur. This preliminary immunomodulatory action helps prevent reactivation of latent virus in nerve ganglia, reducing relapse frequency rather than merely suppressing active replication.
Solution Approach 2:
The immunomodulatory mechanism creates a feedback system where stimulated immune cells continuously monitor and respond to viral presence. This feedback loop provides sustained protection against relapses by maintaining active immune surveillance in the affected area, rather than providing only transient antiviral effects.
Data Source
AI summary
The invention relates to medicine, specifically to new medicinal compositions that exhibit a biocidal, particularly antimicrobial and antiviral, effect. An agent is proposed that contains an alloferon analogue - the peptide H2N-His-Gly-Val-Ser-Gly-His-Gly-Gln-His-Gly-Val-His-Gly-COOH and the peptide HN2-(CH2)10-CO-Ile-Leu-Pro-D-Phe-Lys-D-Phe-Pro-D-Phe-D-Phe-Pro-D-Phe-Arg-Arg-NH2 in a mass ratio from 1:2 to 2:1 and excipients. The agent exhibits a combined antibacterial and antiviral effect and is promising for the treatment of vaginal herpes infection, including when complicated by bacterial infection.